Australia markets closed

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7100-0.0241 (-3.28%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7341
Open0.7230
Bid0.7050 x 2200
Ask0.7126 x 900
Day's range0.7000 - 0.7325
52-week range0.2900 - 3.6200
Volume904,874
Avg. volume2,268,768
Market cap86.019M
Beta (5Y monthly)2.20
PE ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings date04 Aug 2021 - 09 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • We Think Aeterna Zentaris (TSE:AEZS) Can Easily Afford To Drive Business Growth
    Simply Wall St.

    We Think Aeterna Zentaris (TSE:AEZS) Can Easily Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
    GlobeNewswire

    Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

    – Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of its AIM Biologicals pre-clinical program, seeking to develop a potential treatment option for NMOSD, an orphan indication with strong unmet medical need and significant market opportunity CHARLESTON, S.C., June 07, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or

  • Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
    GlobeNewswire

    Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

    CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the U.S. District Court for the District of New Jersey has given final approval of the settlement from the previously disclosed class-action lawsuit against the Company. The settlement payment will be funded entirely